FDA gives expedited approval to new groundbreaking pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted expedited approval to a novel drug called daraxonrasib, designed to combat pancreatic cancer, the deadliest form of the disease. This first-of-its-kind pill blocks a mutated protein responsible for tumor growth in over 90% of pancreatic cancer cases. The daily medication is sold by Revolution Medicines under the brand name Rasonque.

In a study where patients were randomly assigned to receive either the experimental treatment or additional chemotherapy, those taking Rasonque reportedly doubled their survival time while experiencing fewer severe side effects. The study involved 500 patients whose metastatic cancer had ceased responding to prior treatments. The new treatment yielded a median survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy.

Pancreatic cancer is notoriously difficult to detect early, often leading to a grim prognosis. Only about 13% of patients survive for five years. The drug's breakthrough status gained significant public attention after a former US senator, Ben Sasse, shared his positive experience with the medication on CBS's 60 Minutes. The FDA approved the drug over six months ahead of schedule, citing its potential to deliver more cures and treatments to patients quickly.

Pancreatic cancer, which affects nearly 67,000 Americans annually and claims over 52,000 lives, has long posed a challenge due to its early detection difficulties. The drug's mechanism of action involves targeting specific mutations in the Ras gene family, with Kras mutations playing a crucial role in fueling pancreatic cancer growth.

Revolution Medicines' innovative approach uses a "molecular glue" to bind with multiple Kras subtypes, overcoming previous structural barriers that made this cancer driver "undruggable." The company is also exploring the potential of its technology for treating other cancers, including lung cancer.